Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
67%(4 trials)

Phase Distribution

Ph phase_1
4
57%
Ph phase_2
3
43%

Phase Distribution

4

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 23 (42.9%)

Trials by Status

completed686%
withdrawn114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

NCT04321031
completedphase_2

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

NCT04399538
withdrawnphase_1

Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism

NCT04395950
completedphase_2

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03248882
completedphase_1

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

NCT03309202
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04321031Phase 2

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

Completed
NCT04399538Phase 2

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Completed
NCT04395950Phase 1

Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism

Withdrawn
NCT03248882Phase 2

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Completed
NCT03309202Phase 1

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Completed
NCT03597217Phase 1

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Completed
NCT02871037Phase 1

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7